Hikal Q3 FY26: Revenue, EBITDA surge amid regulatory recovery

The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore

Hikal launches HPAPI laboratory at Integrated Innovation Centre, Pune

The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

Briefs: Hikal and Sun Pharma

Sun Pharma gets 8 observations from USFDA for Halol facility

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Hikal invests Rs. 500 crore into fine chemicals plant at Panoli

Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit